bluebird bio - Genetix Biotherapeutics
bluebird bio was renamed Genetix Biotherapeutics in September 2025 after its acquisition by Carlyle and SK Capital in June 2025. The company develops and supplies ex vivo gene therapies for severe rare diseases. The company developed approved therapies for beta-thalassemia, sickle cell disease, and cerebral adrenoleukodystrophy.
- Highest 2026 tier: Tier II
- Cell & Gene Therapy Developers
- 1 ranking category
Overview
bluebird bio was renamed Genetix Biotherapeutics in September 2025 after its acquisition by Carlyle and SK Capital in June 2025. The company develops and supplies ex vivo gene therapies for severe rare diseases. The company developed approved therapies for beta-thalassemia, sickle cell disease, and cerebral adrenoleukodystrophy.
bluebird’s strength is scientific and regulatory pioneering. It helped validate lentiviral vector-based ex vivo gene therapy for severe inherited diseases and brought multiple products through FDA approval. FDA’s approved cellular and gene therapy list includes Zynteglo and Lyfgenia, demonstrating the company’s contribution to the approved gene therapy landscape.
bluebird bio / Genetix Biotherapeutics is included in 1 2026 ranking category. Its highest classification is Tier II. Ranking recognition is category-specific editorial evidence rather than a substitute for independent diligence.
Firm facts
| Public identity | bluebird bio / Genetix Biotherapeutics |
| Founded | 1992 |
| Institution type | Cell & Gene Therapy Developers institution |
| Headquarters | Somerville, United States |
| Primary focus | Cell & Gene Therapy Developers |
| Highest 2026 ranking tier | Tier II |
Contents
Principal activities
bluebird’s strength is scientific and regulatory pioneering. It helped validate lentiviral vector-based ex vivo gene therapy for severe inherited diseases and brought multiple products through FDA approval. FDA’s approved cellular and gene therapy list includes Zynteglo and Lyfgenia, demonstrating the company’s contribution to the approved gene therapy landscape.
Core capability
Cell & Gene Therapy Developers
Client relevance
Category-specific capability, institutional credibility and the ability to support demanding professional, commercial or patient needs.
Execution and verification
Current service scope, leadership, geographic coverage, legal entities and regulated activities should be confirmed directly.
Sector and mandate coverage
Primary category
Cell & Gene Therapy Developers
Institutional context
Coverage reflects the institution’s role in the ranking categories listed below. Precise services, products, jurisdictions, clinical scope and client eligibility should be verified for each use case.
Market position
bluebird’s approved product legacy, scientific contribution, and continuing relevance to the commercialization lessons of gene therapy support its inclusion among established developers, although its business stability is weaker than leading Tier I firms.
bluebird bio / Genetix Biotherapeutics is assessed through public institutional information and Ranking News editorial research. Its strongest 2026 result is Tier II.
Competitive context
The relevant peer set varies by category, geography, client segment and mandate. bluebird bio / Genetix Biotherapeutics should be compared on current category-specific capability, senior involvement, evidence of comparable work, operating resilience and any applicable regulatory or clinical permissions.
Comparable institutions are shown for navigation and market context. Inclusion does not imply identical scale, ownership, geographic coverage, service model or regulatory status.
Leadership and governance
Leadership, ownership, governance and senior-team responsibilities may change. Current information should be verified through authoritative institutional sources.
Corporate and public information
The public-facing organization is identified here as bluebird bio / Genetix Biotherapeutics. Contracting entities, regulated affiliates, clinical operations, offices and legal permissions may differ by service and jurisdiction.
Corporate and disclosure information
| Organization | bluebird bio / Genetix Biotherapeutics |
| Headquarters | Somerville, United States |
| Verification note | Confirm legal entity, licenses, offices and engagement terms directly before appointment or use. |
Additional published ranking appearances
These entries retain the edition, classification and assessed business name published in the source. Historical entries describe that edition, including businesses whose ownership or name later changed.
| Published ranking | Edition / tier | Assessed business |
|---|---|---|
| Top 20 Cell & Gene Therapy Developers 2025 | 2025 · Tier II | bluebird bio / Genetix Biotherapeutics |
| Top 20 Cell & Gene Therapy Developers 2024 | 2024 · Tier II | bluebird bio / Genetix Biotherapeutics |
| Top 20 Cell & Gene Therapy Developers 2023 | 2023 · Tier II | bluebird bio / Genetix Biotherapeutics |
Rankings and recognition
Ranking inclusion and tier classification are editorial determinations. They should be read as category-specific assessments rather than universal league-table positions. The existence or maintenance of this Wiki profile does not influence ranking eligibility, tier or position.
Related Economy analysis
Selected reporting and market analysis from The Economy provides context for the institution’s operating environment:
- Healthcare Rankings and the New Economics of Expertise
- Healthcare Market Structure Is Opening a New Lane for Specialist Providers
- Healthcare Rankings and the New Geography of Distributed Care
Related institutions and subjects
Sources and data transparency
Official institutional information, where available, is used for current public identity and capabilities. Ranking pages document 2026 category and tier status. Economy articles provide market context rather than institution-specific endorsement.
- Healthcare Ranking — Top 30 Cell & Gene Therapy Developers 2026 — 2026 inclusion and tier classification.
- The Economy — Healthcare Rankings and the New Economics of Expertise — market context.
- The Economy — Healthcare Market Structure Is Opening a New Lane for Specialist Providers — market context.
- The Economy — Healthcare Rankings and the New Geography of Distributed Care — market context.
Corrections and Updates
Factual corrections, updated institutional information, and supporting references may be submitted through The Economy Portal. All proposed changes are subject to editorial verification before publication.